[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"parkinson-diseasepd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:parkinson-diseasepd":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,80,107],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100641284","adaptive-dbs-for-pd-100641284",false,"NCT07635823","Adaptive DBS for PD","Adaptive vs Conventional Deep Brain Stimulation for Parkinson's Disease: A Multi-center Randomized Controlled Trial","SMART-DBS","Inclusion Criteria:\n\n* idiopathic Parkinson's disease\n* Hoehn \\& Yahr (HY) stage 2.5-4 during medication \"OFF\"\n* Subjects must meet one of the following:\n\n  1. Never underwent DBS surgery and suitable for bilateral STN or GPi DBS surgery;\n  2. Previous bilateral STN\u002FGPi DBS recipients with only one IPG who:\n* Demonstrate responsiveness to conventional cDBS therapy per investigator evaluation,\n* Consent to device replacement with G1010R DBS system.\n* Willing and physically\u002Fmentally able to complete all study visits and procedures\n* Capable of comprehending and providing written informed consent\n\nExclusion Criteria:\n\n* Presence of contraindications to deep brain stimulation (DBS) surgery.\n* Beck Depression Inventory-II (BDI-II) score \\> 25\n* Mini-Mental State Examination (MMSE) score \\\u003C 24 (adjusted for educational level)\n* Significant comorbidities that may interfere with DBS therapy per investigator assessment.\n* Pre-existing active non-DBS medical implants or metallic cranial implants\n* Requirement for diathermy, transcranial magnetic stimulation (TMS), or electroconvulsive therapy (ECT) during the study period\n* History of ablative neurosurgery or stem cell therapy for Parkinson's disease\n* Inability to complete ≥3 consecutive days of comprehensive motor\u002Fsleep diaries\n* Inability to maintain prescribed medication regimens or comply with protocol requirements\n* Current pregnancy, lactation, or planned pregnancy during the study period\n* Other conditions deemed by investigators to compromise study suitability\n* Participation in other interventional clinical trials within 4 weeks prior to consent","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate the efficacy and safety of an adaptive deep brain stimulation (aDBS) system for managing Parkinson's disease symptoms. Researchers will compare closed-loop stimulation (which automatically adjusts therapy using real-time brain signals and sleep monitoring) against traditional continuous stimulation (fixed settings) in a randomized, double-blind, crossover study. Participants will undergo surgical implantation of PINS Medical's G1010R neurostimulator, followed by alternating treatment phases where each patient experiences both aDBS and conventional open-loop stimulation modes. Outcomes will assess improvements in without troublesome dyskinesia daily time, motor symptoms (e.g., tremors, rigidity), quality of life, and sleep quality across both therapy periods.",[27],"Parkinson Disease(PD)",[29,30,31,32,33],"Parkinson Disease","Deep brain stimulation","Adaptive DBS","Close-loop DBS","Dyskinesia","RECRUITING","2026-06-17",{"date":37,"type":38},"2026-06-22","ACTUAL",{"date":40,"type":38},"2026-05-16",{"date":42,"type":21},"2027-09-30",{"name":44,"class":45},"Beijing Pins Medical Co., Ltd","INDUSTRY",9,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100642045","rhythm-psychophysics-with-parkinsons-patients-100642045","NCT07647913","Rhythm Psychophysics With Parkinson's Patients","RPPD","Inclusion Criteria:\n\n* Parkinson's Disease diagnostic\n* Stage 1 or 2 Hoenh-Yahr scale\n* Taking immediate-release Levodopa\n* MoCA score of 26 or above\n\nExclusion Criteria:\n\n* Dementia\n* Other neurodegenerative disease\n* History of substance abuse\n* History of hearing disorders\n* History of neuropsychiatric disease","40 Years","80 Years",{"count":57,"type":21},34,[24],"The goal of this interventional study is to understand how the rhythmic abilities of individuals in the early stages of Parkinson's Disease (PD) are impacted by their levels of dopamine. The main questions it aims to answer are:\n\n* Does dopamine shelter the ability to generate and maintain a regular tapping rhythm in the presence of disrupting sensory information?\n* Does dopamine allow the adaptation of tapping speed in the presence of changing sensory information?\n* Is the engagement of the motor system useful to improve the detection of changes in the tempo of sensory information?\n\nParticipants will be asked to perform a battery of simple rhythmic tasks On and Off medication to evaluate the effect of dopamine on their rhythmic skills.",[27],[29,62,63,64,65,66,67],"PD","Rhythm","Sensorymotor synchronization","Perceptual timing","Motor timing","Interval timing","NOT_YET_RECRUITING","2026-06-09",{"date":71,"type":38},"2026-06-15",{"date":73,"type":21},"2026-09-01",{"date":75,"type":21},"2027-10-31",{"name":77,"class":78},"McMaster University","OTHER",1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":79},"100614604","objective-mobility-assessment-using-wearable-technology-for-clinical-application-in-parkinsons-disease-from-validation-to-fall-prediction-100614604","NCT07281755","Objective Mobility Assessment Using Wearable Technology for Clinical Application in Parkinson's Disease: From Validation to Fall Prediction","Inclusion Criteria:\n\n* Clinical diagnosis of Parkinson's by a movement disorder specialist according to UK brain bank criteria.\n* Hoehn \\& Yahr stages I-III\n* Able to attend Northumbria University, Newcastle Upon Tyne for study visits\n* Able to walk and stand unassisted for a minimum of 2-minutes\n\nExclusion Criteria:\n\n* History of neurological disorders other than PD (e.g., Huntington's disease, stroke, traumatic brain injury, multiple sclerosis, Alzheimer's disease etc.)\n* Montreal Cognitive Assessment (MoCA) score \\\u003C 21\n* Injury to the lower extremities within the past 6-weeks.","50 Years",{"count":20,"type":21},"OBSERVATIONAL","The main objective of this observational trial is to explore the validity and reliability of DANU smart socks when used for mobility assessments in people with Parkinson's. Using a series of laboratory gold standard equipment, this project aims to compare the metrics observed by DANU to the reference standards. No intervention is included. Specifically, this study will explore metrics relating to walking (gait) and balance of a Parkinson's cohort through a series of motor tasks. Moreover, this study seeks to investigate the clinical validity of DANU outcome metrics exploring relationships with clinical scales, fall history and prospective falls.",[27],[92,93,94,95,96,97],"DANU","Wearable Electronic Devices","Gait Analysis","Validity and Reliability","Mobility Assessment","Smart Socks","2026-02-11",{"date":100,"type":38},"2026-02-12",{"date":102,"type":38},"2025-08-08",{"date":104,"type":21},"2027-09",{"name":106,"class":78},"Northumbria University",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":55,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":117,"conditions":118,"keywords":119,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":79},"100600423","empathy-and-self-compassion-in-parkinsons-disease-patients-and-caregivers-100600423","NCT07097298","Empathy and (Self-)Compassion in Parkinson's Disease Patients and Caregivers","Empathy and (Self-)Compassion to Improve the Quality of Life of Parkinson's Disease Patients and Caregivers: an Exploratory Study","Inclusion Criteria:\n\n* Diagnosis of PD\n* Hoehn and Yahr scale, stage ≤ 3\n* Mini Mental State Examination with a score ≥ 26\n* Able to give informed consent as documented by signature\n* At least, secondary school education\n* To have a regular caregiver at home\n\nExclusion Criteria:\n\n* Any medical condition that is not PD, such as drug induced parkinsonism\n* Major depression, dysthymia, or according to DSM-V\n* Other neurological or psychiatric diseases\n* Neuropsychological scores compatible with the diagnosis of early dementia\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, etc\n\nFor CAREGIVERS:\n\nInclusion criteria\n\n* Taking care of the patient on a regular basis, i.e., at least 3 days per week\n* Being caregiver of the patients for at least 3 months\n* At least, secondary school education\n* Written informed consent",{"count":115,"type":21},30,[24],"The goal of this clinical trial is to improve quality of life in Parkinson's Disease (PD) patients by increasing their empathy and their (self-)compassion. The main question it aims to answer is:\n\nDoes the level of quality of life in PD patients and caregivers improve after empathy\u002F(self-)compassion training?\n\nParticipants will be delivered a 6-week empathy and compassion training (mindfulness, writing and poetry exercises addressing the cognitive, emotional, motivational and behavioural components of (self-)compassion) and will also be asked to answer questionnaires before and after the training",[27],[120,121,122],"Empathy","(self-)compassion","Parkinson disease (PD)","2025-11-24",{"date":125,"type":38},"2025-12-01",{"date":127,"type":38},"2025-11-06",{"date":129,"type":21},"2027-07",{"name":131,"class":78},"Alain Kaelin"]